PCSK9 and familial hyperaldosteronism: PCSK9 inhibitors are currently recommended in the following patient categories: very high-risk secondary prevention patients who are on maximally tolerated statin therapy but have LDL-C greater than 70 mg/dL; patients with statin intolerance and patients with severe primary hypercholesterolaemia (LDL-C > 190 mg/dL), or heterozygous FH who fail despite maximally tolerated therapy [8].